Navion Neurosciences secures $10.8M seed funding for precision sodium-channel medicines targeting genetic epilepsy and ...

Swedish Orphan Biovitrum receives FDA Fast Track Designation for pacritinib (Vonjo) treating VEXAS syndrome. Learn what this ...

CONNECTA Therapeutics secures €3.1M funding to advance CTH120, a TrkB modulator, into mid-stage trials for Fragile X syndrome ...

Ethris GmbH secures €30M EIB financing for broad-spectrum nasal antiviral trials. mRNA respiratory treatment advances to ...

Third Arc Bio selects lead candidate for masked CD3 T cell engager under expanded Adagene collaboration. Milestone payments ...

The US FDA has granted accelerated approval to Hyrnuo (sevabertinib) for the first-line treatment of adults with locally advanced or metastatic non-squamous... Atogepant (Qulipta/Aquipta) met the ...

FDA places partial clinical hold on Biohaven's opakalim epilepsy drug. Impact on pivotal trial timeline and SK Biopharmaceuticals deal revealed.

NeOnc Technologies secures $15M funding to advance Phase II CNS cancer programs following NEO100 efficacy readout. Learn more ...

ViaNautis Bio secures SCI Ventures investment to advance polyNaut platform for chronic spinal cord injury treatment. Discover the breakthrough.

Rezera's ruvonoflast NLRP3 inhibitor met primary endpoint in RESOLVE-1 trial, reducing hsCRP across cardiometabolic patients.

Mindera Health partners with University of Pennsylvania to investigate quinacrine's mechanism in treatment-resistant ...

UpDoc secures $9.2 million ARPA-H funding to develop autonomous heart failure AI system for FDA authorization. Read the ...